Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: microscopic polyangiitis

Predicting the Unpredictable – Taming the Impulse to Treat

Philip Seo, MD, MHS  |  January 17, 2019

One of my fellows could take better care of his patients if it weren’t for the attendings getting in his way. Or so he tells me. I can hear the howls of protest already. This statement isn’t fair—it is too broad, it doesn’t fairly depict the nuances of the situation or his point of view. First,…

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:early arthritisVery Early Rheumatoid Arthritis

FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  January 7, 2019

The FDA has approved Truxima (rituximab-abbs), which is biosimilar to Rituxan (rituximab), for treating adults with CD20-positive, B-cell non-Hodgkin’s lymphoma…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsFDAfilgotinibRheumatoid Arthritis (RA)rituximabrituximab-abbsU.S. Food and Drug Administration (FDA)

AAV Remission Study: Does Rituximab or Azathioprine Work Best?

Thomas R. Collins  |  December 17, 2018

Researchers sought to identify predictors of patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) who took rituximab for maintenance had a better sustained remission rate through 60 months than those taking azathioprine, according to the latest results from the maintenance of remission using rituximab in systemic ANCA-associated vasculitis (MAINRITSAN) trial, a prospective, randomized trial…

Filed under:Research RheumVasculitis Tagged with:ANCA-Associated VasculitisazathioprineMAINRITSANmaintenancerituximab

Rituximab Maintenance Study: Is Fixed-Schedule or Tailored Dosing Best?

Kurt Ullman  |  December 17, 2018

Rheumatologists prescribe rituximab for induction and maintenance treatment for anti-neutrophil cytoplasm antibody (ANCA) associated vasculitides (AAV). Maintenance treatment typically employs fixed-schedule dosing, but in the recent maintenance of remission using rituximab in systemic ANCA-associated vasculitis II (MAINRITSAN2) trial, researchers from the French Vasculitis Study Group examined whether individually tailored maintenance dosing might work better. “The…

Filed under:Research RheumVasculitis Tagged with:ANCA-Associated VasculitisMAINRITSAN2maintenancerituximab

Rituximab Receives Label Update for ANCA-Associated Vasculitis

Michele B. Kaufman, PharmD, BCGP  |  November 26, 2018

The FDA has approved an update for rituximab’s label, which will include safety and efficacy information for treating ANCA-associated vasculitis…

Filed under:Drug Updates Tagged with:FDAGPAgranulomatosis with polyangiitismicroscopic polyangiitis (MPA)U.S. Food and Drug Administration (FDA)

Trimethoprim-Sulfamethoxazole Prophylaxis Reduced Rituximab Infection Risk

Kathy Holliman  |  October 18, 2018

Severe infections occurred in 25% of patients with anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) who were treated with rituximab, according to results of an observational study conducted in the United Kingdom (U.K.) and Austria. Trimethoprim-sulfamethoxazole (TMP/SMX) prophylaxis, however, reduced the risk of severe infections, the investigators reported in Annals of the Rheumatic Diseases.1 Andreas…

Filed under:ConditionsDrug UpdatesVasculitis Tagged with:antibody-associated vasculitisInfectionrituximab

The Promise of Molecular Medicine

Philip Seo, MD, MHS  |  September 19, 2018

Honestly, I’m not sure why I bothered to listen. I was in my kitchen, early on a Saturday morning, with the radio keeping me company. It started with the news and the usual litany of tragedies, both major and minor, that comprise such programs. The news gradually faded into other programming, which I can no…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:Genesgenetics

Cutaneous Lupus Tied to Risk for Coexisting Autoimmune Conditions

Marilynn Larkin  |  May 10, 2018

NEW YORK (Reuters Health)—Patients with cutaneous lupus erythematosus (CLE) should be monitored closely for other autoimmune conditions, researchers suggest. Dr. Benjamin Chong, Dr. Linda Hynan and Elaine Kunzler of the University of Texas Southwestern Medical Center in Dallas analyzed data from 129 adults in the UTSW Cutaneous Lupus Registry (mean age, 49; 79% women). Individuals…

Filed under:Conditions Tagged with:coexisting autoimmune conditionscutaneous lupus erythematosus (CLE)UTSW Cutaneous Lupus Registry

Kussmaul, Meier & Polyarteritis Nodosa

Ruth Jessen Hickman, MD  |  April 26, 2018

In 1866, Adolf Kussmaul, an internist, and Rudolf Maier, a pathologist, published the classic characterization of what eventually became known as polyarteritis nodosa.1 It was the first scientific clinical characterization of a noninfectious vasculitis. As such, it became a paradigmatic point of contrast to other types of vasculitides that were later described. Their description also…

Filed under:Vasculitis Tagged with:HistoryLost & Foundpolyarteritis nodosascientific methodVasculitis

elenabsl / shutterstock.com

Have We Reached the Limits of Clinical Classification?

Philip Seo, MD, MHS  |  April 26, 2018

There is an old adage that there are two types of people—lumpers and splitters. For some, people are easily categorized into liberal vs. conservative, Democrat vs. Republican, Donald Trump supporter vs. Hillary Clinton supporter. For others, everyone is a snowflake, and what makes us different is much more important than what makes us the same….

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:Classification Criteria

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences